The abstract is read at the publisher; the summary is JClub's.
Weekly digital patient-reported outcome monitoring with alert-based nurse/physician follow-up in women with metastatic breast cancer reduced fatigue at 6 months by 5.4 T-score points.
- Why it matters: Electronic PRO monitoring benefits advanced cancer broadly, but metastatic breast cancer–specific evidence is limited, especially for fatigue, a common and functionally impairing symptom.
- What they did: In a multicenter randomized clinical trial in Germany (52 centers; May 2021–Feb 2024), women with mBC on systemic therapy completed weekly smartphone PROs, and predefined deterioration triggered phone contact within 48 hours; controls had quarterly PROs without alerts.
- The result: Among 909 participants in the primary analysis, adjusted fatigue at 6 months was 54.5 vs 59.9 (mean difference -5.4; 95% CI, -6.6 to -4.1; P<.001), exceeding the 3.3-point MCID, and physical functioning improved by 4.0 (95% CI, 2.6-5.4).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.